BioXcel Therapeutics (BTAI) PT Raised to $52 at UBS
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Price: $0.80 --0%
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UBS analyst Colin Bristow raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $52.00 (from $23.00) while maintaining a Buy rating.
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Okta, Inc (OKTA) PT Raised to $165 at JPMorgan
- SentinelOne Inc (S) PT Raised to $22 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
